Replies to post #123989 on Biotech Values

[DewDiligence]

Is there any concern about the effect of TPO agonists on cancer progression and/or survival, as there is with the ESAs?

Excellent question.

[biotech jim]

The only concern I have heard from a couple of hem/oncs has been a surge in platelets and then the concomitant risk of stroke or other clotting issues. I have heard that in the discovery/evaluation of eltrombopag that there was variability in response in native marrow from different donors, some quite strong and others barely detectable. I was not privy to nor have not looked for the individual data from in vivo human studies on the platelet responses, and of course these have not been reported in the oncologic classes of patients for which I have have mentioned (chemo treated patients).

Just curious, but for myelodysplastic syndrome, does the marrow respond to EPO or NEUPO or Neulasta? I guess I should do a pub med search on this.